AFAR is pleased to announce the expansion of the Hevolution-AFAR New Investigator Awards in Aging Biology and Geroscience Research, a grant program to enable early-career investigators with labs in the US and Canada to research healthspan-expanding therapeutics and treatments. Hevolution Foundation, a non-profit organization that provides grants and early-stage investments to incentivize research and entrepreneurship in healthspan science, has awarded the AFAR $16 million to expand the program.
AFAR and the Hevolution Foundation launched the New Investigator Awards in 2022 as a pilot initiative to support research projects in the basic biology of aging or geroscience—a research paradigm based on addressing the biology of aging and age-related diseases to promote healthy aging. In its first cycle, the program generated strong interest in the global aging research community and funded 18 research projects, spanning topics such as cellular senescence, compounds such as metformin and rapamycin, and translational topics such as data-guided drug discovery.
Given the enthusiastic reception from the scientific community and the high quality of the investigators and their research, Hevolution is expanding this program with an additional commitment of $16 million to continue their partnership with AFAR. The funding will provide support in 2023 and 2024 for up to 36 investigators in Canada and the United States with three-year awards of $375,000 each.
The funding commitment was announced at the Hevolution Global Healthspan Summit in Riyadh, on November 30, 2023.
AFAR anticipates announcing the 2023 New Investigators in early 2024.
Explore more perspectives from many of the inaugural New Investigators in AFAR’s Grantee Spotlight Interviews here.
Read a related press release on the expanding funding here.
